Jessica Desnoyer

Jessica Desnoyer Email and Phone Number

CEO | New Business Builder @ Ostiio
Jessica Desnoyer's Location
Greater Boston, United States, United States
Jessica Desnoyer's Contact Details

Jessica Desnoyer personal email

Jessica Desnoyer phone numbers

About Jessica Desnoyer

Jessica is CEO of Ostiio, a seed-stage medical device startup focused on improving the lives of people with craniofacial abnormalities. An accomplished healthcare and life sciences executive, Jessica brings a track record of building innovation centers and emerging businesses within several large corporates (J&J DePuy Synthes, Smith & Nephew, Abbott and Becton Dickinson) to Ostiio. Prior to joining Ostiio, Jessica enjoyed a successful career that encompassed a diverse background across therapy spaces (interventional, cardiovascular and orthopedics), technologies (devices, biologics/biomaterials and combination therapies), and functional leadership roles (R&D, strategy & innovation, marketing, business development and general management). Her education, experience, passion and proven learning agility uniquely position her to guide technology from concept through commercialization. Throughout her career, she has enthusiastically led cross-functional teams to build and execute global operational plans that supported a diverse portfolio of product clearances/approvals and their subsequent commercialization.Most recently, Jessica was Sr Director, Global Strategic Marketing of DePuy Synthes, where she helped drive turnaround of the declining Spine business through leadership of Platform strategy, business development initiatives and commercial execution of the global $250M Biomaterials portfolio. Before that, she was VP, Marketing & Business Development of MicroMedicine, where she helped secure $35M in financing and developed a business plan for the novel microfluidic cell isolation technology startup. Jessica also served as Head of Strategic Innovation for Becton Dickinson’s largest Division, Medication & Procedural Solutions, and established and led Smith & Nephew’s Advanced Healing Technologies franchise, an internal startup aimed at improving outcomes in sports medicine and orthopedic surgery through biologics and biomaterials solutions, which ultimately grew to $70M in revenue. Jessica began her career at Guidant/Abbott Vascular where she helped develop and launch the world’s leading Drug Eluting Stent, the XIENCE/PROMUS system; spearheaded the company’s Vulnerable Plaque program for heart attack prevention; and built the Structural Heart market access strategy, culminating in the acquisition of Evalve.CORE COMPETENCIES:Executive Management | Emerging Businesses | Organization Building | Strategy | Innovation | KOL & Stakeholder Engagement | Global Marketing | Research & Development | Business Development | External Partnerships | P&L Management

Jessica Desnoyer's Current Company Details
Ostiio

Ostiio

View
CEO | New Business Builder
Jessica Desnoyer Work Experience Details
  • Ostiio
    Chief Executive Officer
    Ostiio 2019 - Present
    Boston & Philadelphia, Us
    Ostiio is a seed-stage medical device startup committed to improving the lives of children with craniofacial differences. The treatment experience for these children and their families is often complex and traumatic. At Ostiio, we are working to change that! Our fully implantable, automated device returns control to surgeons and relieves stress from parents and caregivers, transforming the standard of care for this vulnerable patient population.
    View
  • University Of Michigan
    Coulter Translational Research Partnership Program, Oversight Committee
    University Of Michigan 2018 - 2024
    Ann Arbor, Michigan, Us
    The U-M Coulter Translational Research Partnership Program is a commercialization fund that seeks to accelerate the development of university technologies into new products to improve health care. The program funds 5-7 projects per year. Each project must involve a collaboration between UM faculty from any college of engineering department and a practicing clinician from a clinical department.
    View
  • Columbia Technology Ventures
    Executive In Residence
    Columbia Technology Ventures Dec 2022 - Dec 2023
    New York, Ny, Us
    As an Executive in Residence at Columbia Technology Ventures, I will be working with entrepreneurs and inventors at Columbia University to facilitate the transfer of research innovations from the lab to the market, as well as supporting startup efforts. Columbia Technology Ventures, the technology transfer office of Columbia University, manages more than 400 invention disclosures from faculty, 100 license deals and 20+ new startups each year. CTV currently has over 1,500 patent assets available for licensing across research fields such as biopharma, medical devices, software, cleantech, semiconductors, and material science. To learn more about CTV and available inventions, please visit http://www.techventures.columbia.edu/.
    View
  • Depuy Synthes Companies
    Sr Director, Global Strategic Marketing, Spine Platform
    Depuy Synthes Companies 2016 - 2019
    Raynham, Ma, Us
    Recruited to help drive turnaround through leadership of Platform strategy, business development initiatives, and commercial execution of global Biomaterials portfolio.BUSINESS TURNAROUND / EXTERNAL INNOVATION:- Partnered with President to create market insights-driven strategy to reposition business through targeted investment in select portfolio opportunities, external innovation plays, cost improvement measures, and commercial initiatives.- Drove completion of two acquisitions to address portfolio gaps in navigation and nerve monitoring and advanced interbody. - Recovered WW Quarterly Ops Growth from low of -9.5% in Q1’18 to -1.0% in Q1’19 and more than doubled portfolio pipeline value versus year-end 2016. Spine contributed ~45% of total DePuy Synthes 2018 NPI revenue.COMMERCIAL EXECUTION / HIGH GROWTH SEGMENT:- Developed strategy and plan to reposition aging and commoditizing Biomaterials business as focus area and growth driver.- Reinvigorated portfolio by launching ViviGen Formable™, extending lifecycle of flagship cellular bone matrix brand, and PliaFX®, updating demineralized bone matrix line.- Spearheaded exclusive agreement for FIBERGRAFT®, closing portfolio gap in critical advanced synthetics segment.- Drove ~$150MM in US revenue, over-achieving 2018 business plan and delivering >3x market growth.
    View
  • Micromedicine Inc.
    Vice President, Marketing & Business Development
    Micromedicine Inc. 2016 - 2016
    Joined to help CEO secure $35MM financing and develop business plan for novel microfluidic cell isolation technology startup.STARTUP PIVOT:- Overhauled strategy, redirecting focus to applications in clinical research, cell therapy manufacturing, and regenerative medicine, and built operational plan with account-level revenue models that supported capital investment.- Won approval from CEO Founder and Board to pivot strategy within 6 months of company inception.- Built team and hired permanent VP of Marketing and Business Development.
  • Bd
    Head Of Strategic Innovation, Bd Medical - Medication & Procedural Solutions
    Bd 2014 - 2016
    Franklin Lakes, New Jersey, Us
    Tasked to build on legacy of innovation and ensure growth of BD’s largest Division, with annual revenue of ~$3.5B, not dependent on silos of existing business Platforms. Advanced new business opportunities through development and execution of white space, adjacency, and pan-Platform strategies aligned to Division’s mission and purpose.BUSINESS GROWTH STRATEGY / INNOVATION- Built Innovation System and managed Innovation Council, governing body led by Division President. Facilitated opportunity generation and decision-making by advancing steady cadence of new proposals alongside fail fast mentality.- Transitioned 5 programs to product development and crafted Division’s first disease-state specific strategy to transform BD from general-purpose, ancillary player to major partner in care for high burden disease area.
    View
  • Smith & Nephew
    Sr Director & General Manager, Advanced Healing Technologies Franchise
    Smith & Nephew 2012 - 2014
    Watford, Hertfordshire, Gb
    Conceived and led internal startup aimed at improving outcomes following endoscopic soft tissue repair and orthopaedic surgery through solutions addressing underlying biology to enhance healing. Managed $6.6MM budget with direct responsibility for R&D, marketing, and business development and dotted line oversight of cross-functional team.NEW GROWTH FRANCHISE CREATION:- Formulated business plan and secured investment from C-suite to create new growth franchise. Within 90 days, built team of scientists and marketers with competencies needed to realize growth potential.- Developed 5-year strategic plan comprising balanced portfolio of organic and inorganic programs to enable entry into biologics and biomaterials market and to optimize execution with low risk profile.- Established Advanced Healing Technologies, which, with planned peak incremental revenue of $900MM, was positioned to provide aggressive growth for the $3.3B Advanced Surgical Devices Division.- Selected to participate in the inaugural class of the CEO Leadership Forum for development of future executives of the company.PRODUCT DEVELOPMENT & COMMERCIAL EXECUTION- Created KOL advisory board to steer product development, market access, and commercial activities.- Led cross-functional team to institute design and development controls and clarify clinical and regulatory strategy for company’s first drug-device combination product. Initiated pilot clinical study within 18 months.- Delivered next generation platform technology to compete in biocomposite sector of soft tissue fixation device market and launched differentiated HEALICOIL◊ REGENESORB Suture Anchor.- Executed Licensing & Distribution agreements in quick win bone graft substitute and platelet-rich plasma areas. Managed external alliances. Progressed several advanced biologic and biomaterial technologies to late stage diligence.- Drove ~$70MM in revenue in 2014, exceeding plan 12% and delivering 20% growth versus prior year.
    View
  • Smith & Nephew
    Director & General Manager, Advanced Healing Technologies Franchise
    Smith & Nephew 2011 - 2012
    Watford, Hertfordshire, Gb
    View
  • Abbott
    Manager, Strategic Marketing
    Abbott 2008 - 2011
    Abbott Park, Illinois, Us
    Acted as liaison between Division and Abbott Ventures / Corporate Development to enable and drive inorganic growth in accordance with long-range plan.BUSINESS EXPANSION / LICENSING & ACQUISITIONS- Partnered to build strategy comprising licensing, equity investment, and acquisition to enter Structural Heart, considered next major growth market for interventional cardiology. Conducted technical and commercial diligence.- Headed commercial assessment of Evalve, Inc., culminating in upfront $320MM acquisition.
    View
  • Abbott
    Manager, Research & Advanced Development
    Abbott 2007 - 2008
    Abbott Park, Illinois, Us
    Led team of marketing and R&D Therapy Leads while indirectly managing supporting technical and cross-functional teams to deliver innovative, integrated therapies, projected to double the business in the long-range plan, for heart attack prevention, heart failure, and kidney failure.NEW BUSINESS VENTURES EXECUTION- Directed integrated therapy teams to develop and execute global strategic plans, including technology development, market access, and commercialization strategies, for emerging businesses.- Acted as primary interface to executive steering committee and KOL advisory boards, responsibility typically reserved for director-level or higher. Secured continued funding.- These efforts promoted Abbott Vascular’s image as a leading innovator and disruptor in interventional therapies.
    View
  • Abbott
    Emerging Therapy Lead, Heart Attack Prevention
    Abbott 2005 - 2007
    Abbott Park, Illinois, Us
    Responsible for leading integrated therapy team, comprised of technical, marketing, and cross-functional members, to deliver technology development, market access, and commercialization strategies for Heart Attack Prevention emerging business.NEW BUSINESS VENTURES EXECUTION- Guided execution and analysis of PROSPECT, world’s first prospective natural history study designed to correlate angiography, IVUS, and virtual histology imaging of entire coronary tree; biomarkers; and patient demographics to cardiac events.- Steered development of coronary scaffold to stabilize vulnerable lesions and nanoparticle drug delivery technology to reduce coronary plaque burden through controlled release of reverse lipid transport and anti-inflammatory therapeutic agents.
    View
  • Abbott
    Senior Engineer/Principal Engineer
    Abbott 2002 - 2005
    Abbott Park, Illinois, Us
    Helped develop Abbott Vascular’s first drug-eluting stent and initiated next-generation projects.RESEARCH & DEVELOPMENT EXCELLENCE:- Assisted in development of XIENCE V® drug-eluting stent coating, optimizing polymer-drug formulation to attain desired mechanical integrity and drug release profile for clinical safety and efficacy.- Chosen as 1 of 15 personnel to launch XIENCE V® in friendly accounts, allowing sales rep focus on key competitive conversions. Collectively captured >50% market share within 3 months.
    View

Jessica Desnoyer Skills

Cross Functional Team Leadership Medical Devices Commercialization Strategy R&d Product Launch Product Development Market Development Biotechnology Biomedical Engineering Executive Management Business Planning Global Marketing Business Development Fda Leadership Mergers And Acquisitions Program Management Product Marketing Strategic Planning Management P&l Management U.s. Food And Drug Administration Validation Competitive Analysis Product Management Life Sciences Pharmaceutical Industry Entrepreneurship Technology Transfer Orthopedics Regulatory Affairs Orthopedic Lifesciences Research And Development Business Strategy Building Internal And External Relationships Executive Level Communication

Jessica Desnoyer Education Details

  • The Wharton School
    The Wharton School
    Finance
  • University Of Illinois Urbana-Champaign
    University Of Illinois Urbana-Champaign
    Chemical Engineering
  • University Of Michigan
    University Of Michigan
    Chemical Engineering

Frequently Asked Questions about Jessica Desnoyer

What company does Jessica Desnoyer work for?

Jessica Desnoyer works for Ostiio

What is Jessica Desnoyer's role at the current company?

Jessica Desnoyer's current role is CEO | New Business Builder.

What is Jessica Desnoyer's email address?

Jessica Desnoyer's email address is de****@****ail.com

What is Jessica Desnoyer's direct phone number?

Jessica Desnoyer's direct phone number is +140831*****

What schools did Jessica Desnoyer attend?

Jessica Desnoyer attended The Wharton School, University Of Illinois Urbana-Champaign, University Of Michigan.

What are some of Jessica Desnoyer's interests?

Jessica Desnoyer has interest in Development, Insanity Workout Challenges, Endovascular, Vascular, Entrepreneurial, Cardiovascular, Peripheral, Renal, Professional, Biomaterials.

What skills is Jessica Desnoyer known for?

Jessica Desnoyer has skills like Cross Functional Team Leadership, Medical Devices, Commercialization, Strategy, R&d, Product Launch, Product Development, Market Development, Biotechnology, Biomedical Engineering, Executive Management, Business Planning.

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant

Download 750 million emails and 100 million phone numbers

Access emails and phone numbers of over 750 million business users. Instantly download verified profiles using 20+ filters, including location, job title, company, function, and industry.